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Abstract 
 
We investigated the performance of the handheld radial shape discrimination (hRSD) test in 
detecting the development of neovascular AMD (nAMD) in a prospective, longitudinal, 
observational study. Patients diagnosed with unilateral nAMD, with no nAMD in the other eye (the 
study eye, SE), completed the hRSD test on consecutive, routine clinic visits up to a maximum of 
12, or until they were diagnosed with nAMD in the SE based on slit-lamp biomicroscopy and 
spectral-domain OCT assessment, with fluorescein angiography confirmation. Masked grading was 
carried out to confirm the diagnosis of nAMD, and to ensure no cases of nAMD were missed. 
Receiver operating characteristics (ROC) analysis was used to explore the diagnostic performance 
of the hRSD test relative to clinical diagnosis. Data were available from 179 patients of whom 19 
(10.6%; “converters”) developed nAMD in the SE. The mean hRSD threshold at conversion was -
0.47 (95% CI -0.38 to -0.55) logMAR compared to -0.53 (-0.50 to -0.57) logMAR in 160 non-
converters. hRSD threshold in the converters began to decline 190 days before diagnosis of nAMD. 
The ROC curve demonstrated that at an hRSD cut-off of -0.60 logMAR, sensitivity was 0.79 (0.54-
0.94) with a specificity of 0.54 (0.46-0.62); positive and negative predictive values were 0.16 and 
0.96 respectively. We conclude that the hRSD test has moderate sensitivity for detecting the 
earliest stages of nAMD in the at-risk fellow eyes of patients with unilateral nAMD, compared to 
clinical diagnosis. Given its relative inexpensiveness, ease of use and the inherent connectivity of 
the platforms it can be presented on, it may have a role in early detection of nAMD in the 
population at large.   
 
  
Pitrelli Vazquez et al; hRSD testing in nAMD 
-3- 
 
Introduction 
 
Age-related macular degeneration (AMD) is the leading cause of vision loss in developed 
countries, and with the ageing of the population its prevalence is expected to increase[1]. 
However, the prognosis for patients with neovascular AMD (nAMD) has considerably improved 
with the introduction of intravitreal therapy against vascular endothelial growth factor (VEGF). 
Pivotal clinical trials demonstrated that anti-VEGF treatment improves visual acuity (VA) after 
twelve months of monthly treatment, gains that are maintained at 24 months (see Solomon, 2014, 
for review[2]). Longer term follow-up studies have confirmed that treatment leads to a markedly 
improved outcome compared to the devastating visual decline that results from untreated 
nAMD[3, 4]. However, in the real world of rising patient numbers and economic and service 
delivery challenges, outcomes have not been as positive as in the clinical trials[5]. 
 
Early detection and diagnosis of nAMD, leading to earlier treatment, results in better visual 
outcomes[6-10]. However, many patients only seek treatment when they become perceptually 
aware of changes in their vision. Recent analysis of trial and other data has demonstrated 
significant visual loss prior to diagnosis[11]. Screening, self-testing or home monitoring (perhaps 
using some form of tele-monitoring[12]) might facilitate earlier detection, but require appropriate 
tests. Diagnostic testing currently relies on fundus fluorescein angiography (FFA), increasingly 
supplemented by optical coherence tomography (OCT)[13].  These clinic-based approaches are 
relatively expensive, can be time consuming (and in the case of FFA invasive) and none can be self-
administered.  
 
MyVisionTrack (mVT, Vital Art and Science Inc, Dallas, USA) is an application that has FDA approval 
for use in monitoring of macular disease, and runs on a range of mobile devices. The test is based 
on shape perception and exploits the sensitivity of the human visual system to distortions in 
circular radial frequency patterns, in this case circular contours with a cross-sectional luminance 
profile defined by a radial fourth derivative of a Gaussian [14] (see Fig 1 for example stimuli). As 
developed by Wang and colleagues [15-17], these radial frequency patterns are deformed by 
applying a sinusoidal modulation to the radius at a fixed frequency (8 cycles/360°) around the 
circumference. When embedded in a psychophysical staircase procedure, this provides a means of 
determining the minimal radial modulation amplitude necessary to make it possible to distinguish 
a distorted radial frequency pattern from a perfect one, defining a radial shape discrimination 
(RSD) threshold. Because of the sensitivity of the human visual system to these distortions, RSD 
thresholds fall into the hyperacuity range.  While RSD threshold reaches maturity later than 
resolution acuity, once adult thresholds are reached they remain stable in the absence of 
pathology, and are relatively resistant to normal healthy ageing compared to VA[16, 18]. The 
development of AMD has been demonstrated to increase RSD thresholds [15] and test 
performance has been shown to be related to the severity of macular disease[17]. Despite the 
widespread deployment of this test, and its commercial availability (in the form of the mVT 
application in the US), prospectively collected diagnostic performance data is not yet available. 
 
Our objective therefore was to investigate the diagnostic performance of the RSD test, presented 
on a small mobile device (the handheld RSD test, hRSD; the index test), for the detection of nAMD 
using the clinical diagnosis of nAMD, confirmed by FFA, as the reference standard. We followed 
patients who were receiving treatment for nAMD in one eye, whose other eye (the study eye, SE) 
was confirmed to have no nAMD when they entered the study. Because these eyes are considered 
at high risk of developing nAMD, they are routinely monitored[19-21] particularly as development 
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of disease in the second eye has a major impact on the patient’s quality of life. We anticipated 
that this study design would allow us to capture test performance around the time of the 
development of nAMD in a proportion of study eyes[22] and provide summary data for test 
performance in high risk eyes that did and did not develop nAMD and eyes with diagnosed nAMD 
at the initiation of treatment. It would also provide comparative data with alternative tests 
examined using the same study design[22]. 
 
Methods 
Participants  
We conducted a prospective, longitudinal, observational, single centre study that complied with 
the tenets of the Declaration of Helsinki and was approved by an appropriate UK Health Research 
Authority/Research Ethics Committee (North West - Preston Research Ethics Committee; 
13/NW/0449). Written, informed consent was obtained from all participants prior to any study 
procedures. We recruited patients attending a UK National Health Service clinic for the assessment 
and treatment of nAMD in their first eye (FE), whose other eye (the study eye, SE) was clear of 
nAMD, with no other sight threatening macular pathology. Patients were identified and 
approached based on clinical records and previous OCT scans (where available) between 
September 2013 and December 2015.  Inclusion and exclusion criteria are listed in Table 1.  In 
reporting this study we have followed the STARD 2015 guidelines[23]. 
Procedures 
Patients’ study visits were the same day as their standard clinical appointments for assessment 
and treatment of their FE, approximately every 4-12 weeks depending on the anti-VEGF drug they 
were receiving and the stability of their condition. We collected hRSD test data along with data 
from tests performed as part of routine care which included measurement of VA (using EDTRS 
charts) and OCT.  
Table 1. Study inclusion and exclusion criteria. 
Inclusion Criteria Exclusion Criteria 
Over 50 years of age 
 
Willing and able to give informed consent for 
participation 
 
Ability to understand and perform the study 
tests (hRSD test and VA) 
 
Diagnosis of nAMD in the first eye (FE) with no 
nAMD in the study eye (SE) 
Diabetes 
 
SE VA worse than 0.4 logMAR  
 
Other sight threatening conditions affecting the 
macula of the SE, including GA, ERM, VMT, laser 
scars. 
Table 1. SE: Study eye; FE: Eye diagnosed with nAMD; GA: geographic atrophy, ERM: epiretinal membrane, VMT: 
vitreomacular traction 
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The hRSD test was performed using the handheld, spatial, three alternative forced choice (3AFC) 
version of the test presented on an Apple iPod touch (see Wang et al, 2013, for details of the 
test[17]). Briefly, three radial frequency patterns were presented on the iPod screen, one of which 
was distorted by sinusoidal modulation of its radius (Fig 1). A 2-down, 1-up staircase procedure, 
ending after six reversals, was used to estimate the threshold for detecting distortion as the value 
with a 75% correct response rate. The threshold was recorded as a logMAR value. The hRSD test 
was performed on both eyes uniocularly with an optical correction for near (4m prescription plus 
near addition). The right eye was always tested first. Participants held the iPod at a comfortable 
distance and indicated the distorted shape by touching it; they were instructed to guess when 
unsure. The final hRSD score was the average of two consecutive tests or three tests when there 
was a substantial difference between the first two[24]. 
 
Fig 1. Example of the stimuli used in the 
handheld Radial Shape Discrimination (hRSD) 
test[17]. The test employed three radial 
frequency patterns, presented on an Apple 
iPod Touch. The vertical position of each 
pattern was randomly varied, as was the 
position of the target (distorted) pattern (the 
pattern on the right in this example).  
 
 
OCT (Heidelberg Spectralis ) scans of SEs were assessed by an ophthalmologist at each visit. The 
assessing ophthalmologist was always masked with respect to the hRSD result. Diagnosis of nAMD 
was based on OCT, VA and dilated slit-lamp assessment, and in all cases was confirmed with FFA. 
On confirmation, anti-VEGF treatment was initiated. Participants who developed nAMD in the SE 
(“converters”) exited the study at this point (the “conversion visit”). Other participants (“non-
converters”) exited the study having completed up to twelve study visits. For most purposes the 
hRSD threshold at their final visit was used in analysis.   
Two experienced ophthalmologists (authors HH and SPH), masked to the results of the hRSD test, 
independently reviewed the OCTs and FFAs of all the converters to confirm the diagnosis. OCTs 
from visits prior to the clinical conversion visit were reviewed to confirm that no signs of nAMD 
were present prior to the date of the clinical diagnosis of nAMD. The OCT features used to define 
nAMD were diffuse thickening of the retina, intra-retinal cysts, subretinal fluid and subretinal 
hyper reflective material. Serous PED was not considered evidence of nAMD. To confirm absence 
of nAMD development in the SE of non-converters a two-stage grading was carried out. The OCTs 
of all non-converters were reviewed by a single grader (one of the authors, NPV); this identified 
twelve additional patients in whom OCT changes gave rise to a suspicion of conversion. These 
twelve plus a random sample of a further 24 non-converters (15%) were again subjected to 
detailed review by the ophthalmologists. In cases of disagreement, a consensus session was 
organised for adjudication.  
Analysis 
A review of the literature suggested that we could expect approximately 10% of our participants 
to develop nAMD in the SE if we were able to follow them over twelve months. On this basis we 
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recruited a sample of 202 patients to allow us to calculate test sensitivity with 95% CI’s of ±20%. 
Statistical analysis was conducted using SPSS (version 22; IBM Corp., Armonk, NY). Data are 
summarised in the text using the mean and standard deviation (SD) or 95% confidence intervals 
(95% CI). Analysis of variance (ANOVA) was used for multiple comparisons of group parameters; 
p<0.05 was taken to represent a statistically significant result. The receiver operating 
characteristics (ROC) curve was constructed in order to asses test performance with the aim of 
establishing the sensitivity and specificity of the hRSD test for detecting nAMD relative to clinical 
diagnosis with FFA confirmation.   
Results 
Fig 2 illustrates the flow of patients through the study. Of 202 patients recruited, 23 were 
excluded from analysis. Of these, 19 were classed as protocol deviations, consisting of patients 
found not to meet the inclusion/exclusion criteria on post-recruitment review due to 
undocumented lesions in the SE (e.g. geographic atrophy, pigment epithelium detachment, vitreo-
macular traction, epiretinal membrane), or in whom the diagnosis in the FE changed (e.g. from 
nAMD to chronic serous chorioretinopathy, vitelliform lesions, scar, myopic CNV). One further 
patient withdrew from the study and withdrew consent for data collected to be retained, and no 
data were collected from three who were diagnosed with other serious illnesses or died prior to 
data collection commencing. Of the 179 patients (mean age 78±8y; range 52-93y; 107 female, 
60%) who contributed data to the study, 77 completed twelve visits and 130 completed at least six 
visits. Nineteen withdrew having completed fewer than twelve study visits (but permitted us to 
retain their data) and thirty two were lost to follow up because they were discharged from the 
AMD service or stopped attending appointments. At baseline, the mean (±SD) VA, hRSD threshold 
and central subfield thickness (CST) for the study eye (SE) in the final group of 179 patients were 
0.06±0.12logMAR, -0.53±0.22 logMAR and 276±25μm respectively.  
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Fig 2 Diagram demonstrating the flow of study participants. SE: Study eye – no nAMD at recruitment; FE: First eye; 
diagnosis of nAMD, receiving regular assessment and treatment. CSCR: central serous chorioretinopathy; CNV; 
choroidal neovascularisation; GA: geographic atrophy; PED: pigment epithelium detachment; VMT: vitreomacular 
traction; ERM: epiretinal membrane; BRVO: branch retinal vein occlusion; DM: diabetes mellitus. 
 
During the study, 21 patients were identified as having developed nAMD in the SE and listed for 
treatment by their clinicians. Masked grading confirmed the development of nAMD in 18/21, with 
three reclassified as non-converters. Of the 158 non-converters, one was reclassified on masked 
grading. In five of the converters, OCT/FFA review indicated the development of nAMD prior to 
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the clinical diagnosis (one visit before in all cases); the hRSD results from the earlier visit were 
used as the conversion value. In summary, analysis was conducted on 19 confirmed converters 
and 160 confirmed non-converters. 
At baseline, converters and non-converters were indistinguishable in terms of VA (0.05±0.14 
logMAR and 0.06±0.12 logMAR respectively; mean±SD), hRSD threshold (-0.52±0.19 logMAR and -
0.53±0.22 logMAR) and CST (269±26μm and 277±25 μm). The mean ages of converters and non-
converters were 80±7 years and 78±7 years, respectively; these ages were not statistically 
different (t=1.3; p=0.2). We compared VA, hRSD thresholds and CST at baseline and at the 
conversion visit for converters and final study visit for the non-converters (Fig 3). Note that the 
number of visits, and therefore the time between baseline and conversion/final visits, varied both 
within and between groups. VA declined slightly in both converters and non-converters (Fig 3A). 
When tested with a repeated measures ANOVA with group (converter vs non-converters) as a 
between and timepoint (baseline vs final) as a within-subjects factor, timepoint returned a 
statistically significant main effect (F1,174=11,  p=0.001), group did not (F1,174=0.9, p=0.375) and the 
timepoint x group interaction was statistically significant (F1,174=4.6, p<0.03). For hRSD threshold, 
there was a divergence between groups; it improved slightly in the non-converters, while it 
worsened in converters (Fig 3B). When tested with the same design of ANOVA as used for VA, 
neither timepoint nor group returned statistically significant main effects (F1,177=0.03, p = 0.87 and 
F1,177=2.6, p=0.11 respectively); the timepoint x group interaction was statistically significant 
(F1,184=5.7, p=0.018). For CST (Fig 3C) both timepoint and group had a statistically significant effect 
(F1,170=100, p<0.001 and F1,170=31, p<0.001 respectively) and the interaction was also statistically 
significant (F1,170=110, p<0.001). 
 
Fig 3 Mean (±95% CI) baseline and final VA (A), hRSD (B) results and central subfield thickness (CST; C) for 19 
converters (Con) and 160 non-converters (NC). Note that in C the error bars for the non-converter data are smaller 
than the symbols. 
 
We identified 29 patients whose first eye (FE; the eye in which nAMD had been diagnosed), had 
been tested with the hRSD test around the time of their first anti-VEGF injection. Five were newly 
diagnosed and tested prior to their first injection, and 24 were tested no more than one month 
after their first injection. The FE and SE hRSD thresholds were not correlated in these patients. We 
take these thresholds to represent the level of function in patients as they enter treatment. The 
mean FE hRSD threshold was -0.29±0.25logMAR, markedly worse than the SE hRSD threshold at 
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conversion (-0.48±0.19logMAR) or the final hRSD threshold in non-converters (-0.60±0.19; Fig 4). A 
one-way ANOVA of these data returned a statistically significant result (F2,212=30; p<0.001). As 
Levene’s test for the homogeneity of variances returned a statistically significant result (p=0.04) 
for these data, Tamhane’s  T2 post-hoc tests were used to further investigate the group 
differences.  This indicated statistically significant differences between the FE and both SE results 
(SE non-converters p<0.001; SE converters p=0.017); the difference between the SE of converters 
and non-converters did not reach statistical significance (p=0.065). For comparison, we also 
extracted data for a group of healthy eyes we have previously published[18]. The mean hRSD 
threshold calculated for one randomly selected eye from fifty-six healthy participants (mean age 
63±11y), tested with the same 3AFC version of hRSD test as used in the present study, was -
0.71±0.16logMAR. We re-ran the ANOVA, comparing healthy, FE and SE thresholds (F3,363=35; 
p<0.001). Post-hoc testing indicated that the threshold for these healthy participants was 
statistically significantly different from the threshold for the SE of the non-converters as well as 
the other two groups (all p<0.001).   
 
Fig 4 hRSD results for the study eyes in the non-
converters [SE(NC); final visit], the study eyes in 
the converters [SE(C); conversion visit] and eyes in 
which nAMD has been diagnosed tested around 
the time of the first antiVEGF injection (FE). 
Datapoints indicate individual test results, the 
mean (±95% CI) also shown for each group. The 
grey horizontal line and region is the mean (±95% 
CI) hRSD result for healthy eyes, taken from Ku et 
al (2016). The one-way ANOVA result (comparing 
the three patient groups) and post-hoc test results 
(Tamhane’s  T2) are shown for these data. 
 
 
Fig 5 illustrates the timecourse of hRSD performance in converters and non-converters by working 
backwards in time from the conversion visit or final study visit respectively, and fitting all the 
available data using a non-parametric Loess fit. This analysis implied that visual function began to 
decline in the converters approximately 190 days prior to the time at which it was detected 
clinically, and declined at an average rate 
of approximately 0.01 logMAR per month. 
Assuming this rate was maintained as 
disease developed, it would take a further 
476 days for hRSD threshold to decline to 
the FE value of  -0.29±0.23logMAR .  
 
 
Fig 5 Timecourse of hRSD performance in the SE of 
converters (Red) and the SE in the non-converters 
(Blue). Solid lines show the Loess fit (±95% CI) 
calculated by the loess package in R, using a 
default span parameter of 0.75. The fit was 
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aligned on the conversion or final study visit, working back in time. All available data were used. 
 
To address our primary aim of investigating the diagnostic performance of the hRSD test in 
distinguishing converters from non-converters, we constructed the ROC curve (Fig 6). The area 
under the curve (AUC) was 0.69 (95% CI 0.58-0.80), significantly different from the chance level of 
0.5 (p=0.006). The implied optimum hRSD threshold (indicated by the dotted lines in Figure 6) was 
-0.60 logMAR; at this threshold, sensitivity was 0.79 (0.54-0.94) with a specificity of 0.54 (0.46-
0.62). The positive and negative predictive values for the cut-off threshold of -0.60 logMAR were 
0.16 and 0.96 respectively. Table 2 shows the effect of varying the cut-off value for the hRSD 
threshold from -0.70 logMAR to -0.40 logMAR in terms of true and false positive and true and false 
negative results for the current data, with the accompanying negative and positive predictive 
values.  
Table 2. Effect of varying hRSD cut-offs. 
hRSD 
Cut-off 
(logMAR) 
TP 
N (%) 
FP 
N (%) 
TN 
N (%) 
FN 
N (%) 
PPV 
 
NPV 
-0.40 5 (2.8) 
 
25 (14.0) 135 (75.4) 14 (17.8) 0.17 0.91 
-0.50 10 (5.6) 45 (25.1) 115 (65.2) 9 (5.0) 0.18 0.93 
-0.60 15 (8.4) 76 (42.4) 84 (46.9) 4 (2.2) 0.16 0.95 
-0.70 18 (10.1) 108 (60.3) 52 (29.1) 1 (0.56) 0.14 0.98 
Table 2. Relative performance of the hRSD test for a range of cut-off thresholds (from -0.40 logMAR to -0.70 logMAR). 
TP: True positive; FP: False positive; TN: True negative; FN: False negative; figures given as N and the percentage of 
the total sample of our 179 participants categorised. PPV and NPV: positive and negative predictive values 
respectively. The study prevalence of nAMD was 10.6%. 
 
Fig 6 Receiver operating characteristics (ROC) 
curve for the performance of the hRSD test in 
distinguishing between converters and non-
converters (ie detecting the earliest stage of 
nAMD). The area under the curve (AUC; 95% 
confidence interval) and accompanying p value are 
shown. Dotted lines indicate a sensitivity of 0.79 
and a specificity of 0.54 at an hRSD threshold of -
0.60 logMAR. 
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Discussion 
It has been shown previously that hRSD test results are stable and repeatable in healthy eyes[18], 
are affected by the development of macular disease, and are related to disease severity[17]. We 
used a prospective, longitudinal, observational study design similar to that of Do et al (2012)[22] 
and followed the disease-free eyes of patients being treated for unilateral nAMD. Our results 
confirm that, at the earliest stages of clinically detectable disease, hRSD test results are worse in 
eyes that develop nAMD compared to those that do not. A cross-sectional ROC analysis indicated 
moderate test performance in detecting the development of the earliest stages of nAMD 
compared to the reference standard (OCT and slit-lamp biomicroscopy with FFA confirmation).  
It is difficult to directly compare our hRSD results with those published previously because of 
differences in patient selection and study design. Wang et al (2013)[17] reported a mean hRSD 
threshold of -0.36 (95% CI -0.24 to -0.48) logMAR for 11 eyes with intermediate AMD (defined as 
presence of large drusen and/or pigmentary changes). The mean (±SD) VA in these patients was 
0.23±0.2 logMAR. This hRSD result is worse than the SE baseline hRSD threshold in our 160 non-
converters (-0.53 [95% CI -0.50 to -0.57] logMAR). However, we recruited study participants on the 
basis of no nAMD (or other macular pathology) in the SE, and did not specify a particular level of 
intermediate AMD. This, along with a much better VA of 0.08±0.15 logMAR in our non-converters, 
suggests fundamental differences between the groups. Our non-converters’ hRSD performance 
was significantly worse than that of healthy participants (mean -0.71 logMAR; see the ANOVA 
result above and Fig 4) consistent with a decline in hRSD performance prior to the development of 
nAMD.  
Wang et al (2013)[17] also reported a mean hRSD threshold in a group of 16 patients with 
“advanced AMD” (defined as either GA or exudative disease) as -0.13 (95% CI -0.02 to -0.19) 
logMAR. Given the mixed nature of this group, including some who had received anti-VEGF 
therapy, it is not directly comparable to the converters in our study (hRSD threshold at conversion 
-0.47[95% CI -0.38 to -0.55] logMAR). And it is also worse than that observed in 29 FE’s in our 
patients around the time of their first anti-VEGF injection (-0.29 [95% CI -0.20 to -0.38] logMAR).  
We were able to construct the time course of hRSD threshold change in converters and non-
converters, working back from the point of diagnosis or the final threshold measured respectively, 
(Fig 5). While these data should be interpreted with care, they do suggest functional change prior 
to the evidence of structural change in the central retina detected by OCT which prompts 
diagnosis. This is subtle and is observed in the average performance of the groups, rather than in 
individual patients. What is surprising is the relatively long period over which it occurs. Because 
converters left the study at the conversion visit and embarked on treatment, we do not know the 
rate of change in hRSD threshold as nAMD progresses in the absence of treatment. But these data 
highlight that there may be a relatively wide time window within which detection and intervention 
could be improved relative to current practice. If hRSD threshold were to decline at the same rate 
after conversion, and if we assume that the FE hRSD threshold (-0.29 logMAR) is representative of 
patients currently embarking on treatment, then this implies a period of 476 days between 
conversion and treatment. However, it seems more plausible that function might decline more 
rapidly post conversion, with the accumulation of fluid and structural disruption that might be 
expected, prompting testing and diagnosis in a shorter period than this implies. A recent review 
concluded that in the transition from intermediate AMD to diagnosed nAMD, VA can decline by 3-
5 lines, with many patients having nAMD for 6-12 months before treatment is initiated[11]. In this 
general context the hRSD test could have value in prompting earlier diagnosis and treatment. 
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We found diagnostic performance of the hRSD test, in detecting the earliest stages of nAMD, to be 
moderate against the reference standard of spectral-domain OCT, slit lamp biomicroscopy and 
FFA. There are alternative tests, which, like the hRSD test, could be deployed away from busy 
assessment and treatment clinics to monitor macular vision, particularly in at-risk eyes[25]. 
Perhaps most familiar is the Amsler Grid test[26], which is widely used. The ForeseeHome 
Preferential Hyperacuity Perimeter (PHP; Notal Vision Ltd, Tel Aviv, Israel) tests alterations to 
Vernier hyperacuity (similar in principle to testing radial shape discrimination[27]) and has also 
been approved by the FDA in the US for monitoring macular vision. In small studies it has been 
claimed to have good performance in detecting the occurrence of nAMD in at-risk eyes[28]. It has 
also been demonstrated that use of the ForeseeHome device in home monitoring prompts earlier 
treatment as the development of choroidal neovascularisation (CNV) is detected earlier compared 
to normal care [29].  
Faes et al (2014)[30] conducted a metanalysis of studies examining both the Amsler grid and PHP 
for the detection of nAMD. The pooled sensitivity of studies assessing the Amsler grid was 0.78 
(95% CI 0.64–0.87), and the pooled specificity 0.97 (95% CI 0.91–0.99). For PHP they reported a 
pooled sensitivity of 0.85 (95% CI 0.80–0.89), and specificity of 0.87(95% CI 0.82–0.91). However, 
as they pointed out, many of the studies included in the analysis were small case-control series. 
These tend to exclude difficult to diagnose cases and therefore artificially boost the apparent 
sensitivity and specificity[31]. This tendency is further exacerbated by the inclusion of studies in 
which healthy participants are compared to patients with established disease. The apparent level 
of diagnostic performance implied by the high sensitivities and specificities generated by Faes et 
al. (2014)[30] is not likely to be achieved in clinical practice. 
Importantly Do et al. (2012)[22] followed the unaffected fellow eye of patients with unilateral 
nAMD (the same study design which we adopted) and investigated the performance of time 
domain OCT, PHP and supervised Amsler grid in detecting nAMD, presenting data from a group of 
87 patients who had a baseline median age of 79y and identical baseline VA and similar gender 
balance to our sample. Of their 87 patients, 13 (15%) converted to nAMD in the study eye. This 
study design allows for a more clinically relevant assessment, particularly for early detection of 
nAMD. At the outset patients cannot be classified into the required diagnostic categories (i.e. 
nAMD vs non-nAMD) so there is no scope for the “diagnostic bias” that might be present in case-
control designs. The discrimination to be made is also closer to that being made clinically i.e. 
between intermediate AMD and new-onset nAMD, not between healthy eyes and those with 
established disease. Not surprisingly the sensitivities for both Amsler grid and PHP were markedly 
lower than those reported by Faes et al (2014)[30] at 0.42 (95% CI 0.15–0.72), and 0.50 (95% CI 
0.23–0.77) respectively[22]. These results provide a valid comparison with our data given the 
similarity in patients recruited and study design. On this basis, the performance of the hRSD test in 
our study (sensitivity: 0.79 [95% CI 0.54-0.94]; specificity of 0.54 [95% CI 0.46-0.62] at a threshold 
of -0.60logMAR) compares favourably with these alternatives.  
Caution should be exercised in comparing the performance of the hRSD test we have reported 
using this prospective study design, and the performance of other tests which have followed 
alternative designs, given the potential for bias noted above. Our aim was to investigate a single 
test (ie the hRSD) compared to a widely recognised clinical reference standard. It was also to 
assess the performance of the hRSD for detecting nAMD at an early stage, around the time it can 
be diagnosed (hence the longitudinal nature of the study). Clearly there would be value in 
comparing a number of tests to the same reference standard in a single study with the same 
prospective design.  
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Given the moderate sensitivity and low specificity of the hRSD test, the manner in which it might 
be deployed must be carefully considered. The comparative values for the positive and negative 
predictive values (PPV and NPV; Table 2) suggest a role in ruling out disease and providing 
reassurance to patients away from clinic settings. However, our study prevalence of nAMD (10.6%) 
is obviously much higher than its population prevalence. Population prevalence is influenced by 
many factors including age and ethnic origin[1]. For a Caucasian population aged 70-80y a 
prevalence of approximately 2% is realistic[1, 32]. Using the sensitivity and specificity of the hRSD 
test for a cut-off value of -0.60 logMAR, and assuming a prevalence for nAMD of 2%, yields a PPV 
of 0.03 and NPV of 0.99. However, as Table 2 illustrates, a cut-off of -0.60 logMAR is likely to 
generate a high number of false positive results. These can be reduced by using a more positive 
cut-off without materially changing the PPV and NPV. Using a cut-off of -0.50 logMAR (essentially 
sacrificing sensitivity) reduces false positives by half; at a prevalence of 2% the PPV and NPV are 
0.04 and 0.99. Increasing the cut-off and reducing sensitivity has the inevitable effect of also 
increasing false negatives. However, in the case of attempted earlier detection of nAMD, a patient 
with a false negative result would be no worse off than in current practice. If nAMD was present, 
function would continue to decline until a retest detected it or symptoms prompted assessment, 
diagnosis and treatment.  
Our study has a number of limitations. The issue of the influence of treatment in one eye on the 
conversion rate in the other eye has been addressed in a retrospective analysis of data from the 
ANCHOR and MARINA trials; monthly ranibizumab injections were not found to lower the 
conversion rate in fellow eyes[33]. Analysis of data from the CATT trial found no statistically 
significant difference in the conversion rate in fellow eyes between ranibizumab and 
bevacizumab[34]. However, our aim was to capture a suitable number of patients at the earliest 
stages of the development of nAMD in order to assess the performance of the hRSD test. Whether 
first or second eyes are being monitored with the test is unlikely to affect that performance. 
Another limitation of our study is that other than establishing that nAMD was not present in the 
SE, we did not characterise what level of early or intermediate AMD was present. The SE was 
identified as being “at risk” because of disease in the first eye. So these results are likely to be 
most applicable to settings in which a heterogeneous population is being monitored.   
The importance of monitoring the unaffected eye in patients being treated for unilateral nAMD 
has recently been highlighted using real-world data[35]. Particularly in treat-and-extend regimens, 
as intervals between assessments increase in length, our data suggest that the hRSD test might 
have a role in monitoring these eyes, particularly given that this can be accomplished 
remotely[24]. Our patients found the test easy to use and the instructions easy to follow, as has 
been reported previously[17, 36]. A further application might be in primary care settings, where 
the high NPV might be useful in reducing false positive referrals to hospital AMD clinics.   
In the context of frequent late presentation, relatively inexpensive self-monitoring with the hRSD 
test of people at risk of losing vision from nAMD offers potential for preserving vision. Our findings 
imply an extended time window within which earlier diagnosis and treatment might be possible. 
Future research on the deployment of the hRSD test within clinical pathways should aim to define 
appropriate target populations such as the general elderly population, at risk eyes, fellow eyes of 
affected patients and/or eyes undergoing treatment/monitoring. 
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